Biomarker combination for colorectal cancer early diagnosis and use thereof

Abstract

The present invention belongs to the field of colorectal cancer detection, and particularly relates to a biomarker combination for colorectal cancer early diagnosis and a use thereof. The present invention specifically discloses a use of the biomarker in colorectal cancer early diagnosis. The combination of a determination of the biomarker and a fecal occult blood test for the colorectal cancer early diagnosis has the advantages of low cost, convenience in detection, high accuracy, good sensitivity and strong specificity, and avoids pain, discomfort and complications caused by invasive colonoscopy, remarkably decreases the false positive rate of the colorectal cancer early diagnosis, and is able to be widely applied to the colorectal cancer early diagnosis.

Dependencies are inferred from the claim text.